PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $93.00. The company’s shares closed last Friday ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

The BioNTech SE ADR BNTX rallied 1.00% to $124.71 Tuesday, on what proved to be an all-around mixed trading session for the ...

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...